Our Science

Pipelines

Pipelines

Disease Area Product Modality Indication 2021 2022 (E) 2023 (E) 2024 (E) 2025 (E) 2026 (E)
Oncology AMB302 ADC GBM, bladder
Late
Discovery
Pre-clinical
Phase 1a
AMB015 ADC Hematologic
& solid tumors
Late Discovery
Pre-clinical
Phase 1a
AMB018 mAb Solid tumors
Late Discovery
Pre-clinical
Phase 1a
Neurodeg
enerative
AMB011 mAb Dementia
Late Discovery
Pre-clinical
Phase 1a
AMB001 mAb Brain diseases
Late Discovery
Pre-clinical
Phase 1a
BBB crossing AMB016 bsAb Brain diseases
Late Discovery
Pre-clinical
Phase 1a
Oncology
  • Late-Discovery
  • Pre-Clinical
  • Phase 1a
Product Modality Indication
AMB302 ADC GBM,
Bladder Cancer
images

Undisclosed ADC program that utilizes AIMEDBIO’s proprietary antibody targeting a fusion protein in glioblastoma

Product Modality Indication
AMB015 ADC Hematologic &
solid tumors
images

AMB015 is an undisclosed program that utilizes AIMEDBIO’s proprietary ADC platform technology, consisting of a novel payload with outstanding efficacy in glioblastoma.

Product Modality Indication
AMB018 mAb Solid tumors
images

AMB018 is a monoclonal antibody that targets and suppresses tumor-associated macrophages (TAM) present in solid tumors.

Neurodegenerative
  • Late-Discovery
  • Pre-Clinical
  • Phase 1a
Product Modality Indication
AMB011 mAb Dementia
images

AMB011 is designed to treat neurodegenerative diseases by targeting a cell surface receptor expressed on myeloid-lineage cells.

Product Modality Indication
AMB001 mAb Brain diseases
images

AMB001 is designed to treat multiple sclerosis and neurodegenerative diseases by targeting a cell surface receptor expressed on microglia.

BBB Crossing
  • Late-Discovery
  • Pre-Clinical
  • Phase 1a
Product Modality Indication
AMB016 bsAb Brain diseases
images

AMB016 is a bispecific antibody that is engineered to combine AIMEDBIO’s proprietary BBB penetrating platform with a CNS disease drug.

AMB302 AMB302 is an undisclosed ADC program that utilizes AIMEDBIO’s proprietary antibody targeting a fusion protein in glioblastoma.
AMB015 AMB015 is an undisclosed program that utilizes AIMEDBIO’s proprietary ADC platform technology, consisting of a novel payload with outstanding efficacy in glioblastoma.
AMB018 AMB018 is a monoclonal antibody that targets and suppresses tumor-associated macrophages (TAM) present in solid tumors.
AMB011 AMB011 is designed to treat neurodegenerative diseases by targeting a cell surface receptor expressed on myeloid-lineage cells.
AMB001 AMB001 is designed to treat multiple sclerosis and neurodegenerative diseases by targeting a cell surface receptor expressed on microglia.
AMB016 AMB016 is a bispecific antibody that is engineered to combine AIMEDBIO’s proprietary BBB penetrating platform with a CNS disease drug.
Disease Areas >>